{"DataElement":{"publicId":"2974158","version":"1","preferredName":"Paroxysmal Nocturnal Hemoglobinuria Laboratory Procedure Performed Type","preferredDefinition":"A description of the type of laboratory procedure that was performed for the paroxysmal nocturnal hemoglobinuria.","longName":"2974136v1.0:2974148v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2974136","version":"1","preferredName":"Paroxysmal Nocturnal Hemoglobinuria Laboratory Procedure Performed","preferredDefinition":"A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis.  The episodes of hemolysis tend to occur at night.  It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.","longName":"P_N_H_L_P_P","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2974133","version":"1","preferredName":"Paroxysmal Nocturnal Hemoglobinuria Laboratory Procedure","preferredDefinition":"No Value Exists:Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","longName":"C61233:C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paroxysmal Nocturnal Hemoglobinuria","conceptCode":"C61233","definition":"A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BCE5DFC-2BEE-AF37-E040-BB89AD4368D2","latestVersionIndicator":"Yes","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"ONEDATA","dateModified":"2009-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2241241","version":"1","preferredName":"Performed","preferredDefinition":"Performed; carried out.","longName":"C38000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FA7953-8839-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-08","modifiedBy":"ONEDATA","dateModified":"2005-07-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BCE5DFC-2C0D-AF37-E040-BB89AD4368D2","latestVersionIndicator":"Yes","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2974148","version":"1","preferredName":"Paroxysmal Nocturnal Hemoglobinuria Laboratory Procedure Type","preferredDefinition":"A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Type; a subdivision of a particular kind of thing.","longName":"P_N_H_L_P_T","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other test","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BCE5DFC-2C7F-AF37-E040-BB89AD4368D2","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"ONEDATA","dateModified":"2009-12-28","deletedIndicator":"No"},{"value":"Sugar water / sucrose lysis test","valueDescription":"Sucrose Lysis","ValueMeaning":{"publicId":"2974149","version":"1","preferredName":"Sucrose Lysis","longName":"2974149","preferredDefinition":"A disaccharide consisting of glucose and fructose. The linkage is alpha with respect to the glucose and beta with respect to the fructose.: Rupture of cell membranes and loss of cytoplasm. (On-line Medical Dictionary)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sucrose","conceptCode":"C68477","definition":"A disaccharide consisting of glucose and fructose. The linkage is alpha with respect to the glucose and beta with respect to the fructose.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tissue Lysis","conceptCode":"C37889","definition":"Tissue structure disintegration and destruction due to action of endogenous or/and exogenous lytic substances which include but not limited to naturally occurring or laboratory designed proteolytic enzymes, glycosidases, detergents, pore-forming proteins, immune complexes, etc. Tissue lysis plays role in pathogenesis of a number of conditions e.g. protozoal infections, ischemic tissue injury, and autoimmune disorders. It is also used as a basis for non-surgical treatment modality to remove or minimize presence of abnormal tissue, e.g. adhesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BCE5DFC-2C8C-AF37-E040-BB89AD4368D2","latestVersionIndicator":"Yes","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BCE5DFC-2CA5-AF37-E040-BB89AD4368D2","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"ONEDATA","dateModified":"2009-12-28","deletedIndicator":"No"},{"value":"Hemosiderinuria","valueDescription":"Urine Discoloration","ValueMeaning":{"publicId":"2943916","version":"1","preferredName":"Urine Discoloration","longName":"2943916","preferredDefinition":"Change in the color of the urine. Causes include medications, vitamins, urinary tract infection, liver disease, hemolysis, and kidney cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urine Discoloration","conceptCode":"C78678","definition":"Change in the color of the urine. Causes include medications, vitamins, urinary tract infection, liver disease, hemolysis, and kidney cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"742B7AFC-1849-7F97-E040-BB89AD43448E","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BCE5DFC-2CDF-AF37-E040-BB89AD4368D2","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"ONEDATA","dateModified":"2009-12-28","deletedIndicator":"No"},{"value":"Ham's acid hemolysis test","valueDescription":"Acid Hemolysis","ValueMeaning":{"publicId":"2974151","version":"1","preferredName":"Acid Hemolysis","longName":"2974151","preferredDefinition":"A substance that yields hydrogen ions or protons in aqueous solutions; a substance capable of accepting a pair of electrons for the formation of a coordinate covalent bond; a substance whose hydrogen can be replaced by metals or basic radicals, or which react with bases to form salts and water.: Disruption of the integrity of the red cell membrane causing release of hemoglobin. (On-line Medical Dictionary)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acid","conceptCode":"C48057","definition":"A substance that yields hydrogen ions or protons in aqueous solutions; a substance capable of accepting a pair of electrons for the formation of a coordinate covalent bond; a substance whose hydrogen can be replaced by metals or basic radicals, or which react with bases to form salts and water.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hemolysis","conceptCode":"C37965","definition":"Disruption of the integrity of the erythrocyte membrane causing release of hemoglobin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BCE5DFC-2CEC-AF37-E040-BB89AD4368D2","latestVersionIndicator":"Yes","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BCE5DFC-2D05-AF37-E040-BB89AD4368D2","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"ONEDATA","dateModified":"2009-12-28","deletedIndicator":"No"},{"value":"Flow cytometry for CD55 / CD16 / CD59","valueDescription":"Complement Decay-Accelerating Factor Fc-Gamma Receptor III CD59 Glycoprotein Flow Cytometry","ValueMeaning":{"publicId":"3203134","version":"1","preferredName":"Complement Decay-Accelerating Factor Fc-Gamma Receptor III CD59 Glycoprotein Flow Cytometry","longName":"3203134","preferredDefinition":"Complement decay-accelerating factor (381 aa, ~41 kDa) is encoded by the human CD55 gene. This protein plays a role in the negative regulation of the complement cascade.: Fc-Gamma Receptor III is expressed on natural killer cells, granulocytes, and monocytes.  It is included in the zeta natural killer cell receptor complex.  Fc receptor III is encoded by two separate genes: one for the neutrophil receptor (CD16) and another for the receptor on natural killer cells and macrophages.  Some gamma-delta T-cells express CD16.  Mitogenic stimulation of circulating gamma-delta T-cells results in decreased expression of CD16.: CD59 glycoprotein (128 aa, ~14 kDa) is encoded by the human CD59 gene. This protein is involved in the inhibition of the assembly of the membrane attack complex in the complement cascade.: A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complement Decay-Accelerating Factor","conceptCode":"C95931","definition":"Complement decay-accelerating factor (381 aa, ~41 kDa) is encoded by the human CD55 gene. This protein plays a role in the negative regulation of the complement cascade.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Fc-Gamma Receptor III","conceptCode":"C17487","definition":"A family of low affinity receptors that bind to the Fc region of gamma immunoglobulin (IgG) monomers and aggregates. These receptors are expressed on the surface of natural killer cells, neutrophils, monocytes and macrophages. IgG binding initiates antibody-dependent cellular cytotoxicity and induces phagocytosis of antigen-antibody complexes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"CD59 Glycoprotein","conceptCode":"C95934","definition":"CD59 glycoprotein (128 aa, ~14 kDa) is encoded by the human CD59 gene. This protein is involved in the inhibition of the assembly of the membrane attack complex in the complement cascade.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Flow Cytometry","conceptCode":"C16585","definition":"A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E7673D8-98FE-F3B3-E040-BB89AD431036","latestVersionIndicator":"Yes","beginDate":"2011-03-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-03-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9E7673D8-9917-F3B3-E040-BB89AD431036","beginDate":"2009-12-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-03-14","modifiedBy":"ONEDATA","dateModified":"2011-03-14","deletedIndicator":"No"},{"value":"PIGA GPI anchor protein defect","valueDescription":"Phosphatidylinositol N-Acetylglucosaminyltransferase Subunit A Protein Defect","ValueMeaning":{"publicId":"3203135","version":"1","preferredName":"Phosphatidylinositol N-Acetylglucosaminyltransferase Subunit A Protein Defect","longName":"3203135","preferredDefinition":"Phosphatidylinositol N-acetylglucosaminyltransferase subunit A (484 aa, ~54 kDa) is encoded by the human PIGA gene. This protein is involved in the mediation of glycophosphoinositol anchor synthesis.: Any of a group of complex organic macromolecules that contain carbon, hydrogen, oxygen, nitrogen, and usually sulfur and are composed of one or more chains of amino acids. Proteins are fundamental components of all living cells and include many substances, such as enzymes, hormones, and antibodies, that are necessary for the proper functioning of an organism.: A failing or deficiency.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phosphatidylinositol N-Acetylglucosaminyltransferase Subunit A","conceptCode":"C95927","definition":"Phosphatidylinositol N-acetylglucosaminyltransferase subunit A (484 aa, ~54 kDa) is encoded by the human PIGA gene. This protein is involved in the mediation of glycophosphoinositol anchor synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Protein","conceptCode":"C17021","definition":"A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Defect","conceptCode":"C43429","definition":"A failing or deficiency.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E7673D8-9925-F3B3-E040-BB89AD431036","latestVersionIndicator":"Yes","beginDate":"2011-03-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-03-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9E7673D8-993E-F3B3-E040-BB89AD431036","beginDate":"2009-12-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-03-14","modifiedBy":"ONEDATA","dateModified":"2011-03-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2974147","version":"1","preferredName":"Paroxysmal Nocturnal Hemoglobinuria Laboratory Procedure Type","preferredDefinition":"No Value Exists:Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.:Type; a subdivision of a particular kind of thing.","longName":"C61233:C25294:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paroxysmal Nocturnal Hemoglobinuria","conceptCode":"C61233","definition":"A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BCE5DFC-2C50-AF37-E040-BB89AD4368D2","latestVersionIndicator":"Yes","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"ONEDATA","dateModified":"2009-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BCE5DFC-2C61-AF37-E040-BB89AD4368D2","latestVersionIndicator":"Yes","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"KUMMEROA","dateModified":"2012-04-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedObservation:methodCode","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What paroxysmal nocturnal hem","type":"Preferred Question Text","description":"What paroxysmal nocturnal hemoglobinuria test was used?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2974158","type":"BRIDG Mapping Path","description":"PerformedObservationResult > PerformedObservation.methodCode WHERE PerformedObservation > DefinedObservation.nameCode = \"Test for Paroxysmal Nocturnal Hemoglobinuria\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BCE5DFC-2D47-AF37-E040-BB89AD4368D2","latestVersionIndicator":"Yes","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"KUMMEROA","dateModified":"2021-08-16","changeDescription":". 2021-8-16 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}